GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » POINT Biopharma Global Inc (NAS:PNT) » Definitions » Equity-to-Asset

POINT Biopharma Global (POINT Biopharma Global) Equity-to-Asset : 0.89 (As of Sep. 2023)


View and export this data going back to 2020. Start your Free Trial

What is POINT Biopharma Global Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. POINT Biopharma Global's Total Stockholders Equity for the quarter that ended in Sep. 2023 was $424.2 Mil. POINT Biopharma Global's Total Assets for the quarter that ended in Sep. 2023 was $477.7 Mil. Therefore, POINT Biopharma Global's Equity to Asset Ratio for the quarter that ended in Sep. 2023 was 0.89.

The historical rank and industry rank for POINT Biopharma Global's Equity-to-Asset or its related term are showing as below:

PNT' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.61   Med: 0.92   Max: 0.97
Current: 0.89

During the past 3 years, the highest Equity to Asset Ratio of POINT Biopharma Global was 0.97. The lowest was 0.61. And the median was 0.92.

PNT's Equity-to-Asset is not ranked
in the Biotechnology industry.
Industry Median: 0.67 vs PNT: 0.89

POINT Biopharma Global Equity-to-Asset Historical Data

The historical data trend for POINT Biopharma Global's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

POINT Biopharma Global Equity-to-Asset Chart

POINT Biopharma Global Annual Data
Trend Dec20 Dec21 Dec22
Equity-to-Asset
0.61 0.97 0.84

POINT Biopharma Global Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.95 0.84 0.85 0.90 0.89

Competitive Comparison of POINT Biopharma Global's Equity-to-Asset

For the Biotechnology subindustry, POINT Biopharma Global's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


POINT Biopharma Global's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, POINT Biopharma Global's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where POINT Biopharma Global's Equity-to-Asset falls into.



POINT Biopharma Global Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

POINT Biopharma Global's Equity to Asset Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Equity to Asset (A: Dec. 2022 )=Total Stockholders Equity/Total Assets
=486.954/578.323
=0.84

POINT Biopharma Global's Equity to Asset Ratio for the quarter that ended in Sep. 2023 is calculated as

Equity to Asset (Q: Sep. 2023 )=Total Stockholders Equity/Total Assets
=424.192/477.704
=0.89

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


POINT Biopharma Global  (NAS:PNT) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


POINT Biopharma Global Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of POINT Biopharma Global's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


POINT Biopharma Global (POINT Biopharma Global) Business Description

Traded in Other Exchanges
N/A
Address
4850 West 78th Street, Indianapolis, IN, USA, 46268
POINT Biopharma Global Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of radioligand therapies for the treatment of cancer. Its product pipeline includes PNT2002; PNT2004; PNT2003; PNT2001 and others.
Executives
Biotechnology Value Fund L P other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Partners L P/il 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Gp Holdings Llc 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Ii Gp Llc other: See Explanation of Responses 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf I Gp Llc other: See Explanation of Responses 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Partners Os Ltd. other: See Explanation of Responses P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Biotechnology Value Trading Fund Os Lp other: See Explanation of Responses P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Mark N Lampert 10 percent owner 1 SANSOME ST, 30TH FL, SAN FRANCISCO CA 94104
Biotechnology Value Fund Ii Lp other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Inc/il 10 percent owner 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bridget A Martell director C/O POINT BIOPHARMA GLOBAL INC., 4850 WEST 78TH STREET, INDIANAPOLIS IN 46268
Joe A. Mccann director, officer: Chief Executive Officer 4850 WEST 78TH STREET, INDIANAPOLIS IN 46268
Rajesh Malik director 79 TW ALEXANDER DRIVE, 4501 RESEARCH COMMONS, SUITE 100, RESEARCH TRIANGLE PARK NC 27709
Gerald L. Hogue director 4850 WEST 78TH STREET, INDIANAPOLIS IN 46268
David Charles Lubner director C/O TETRAPHASE PHARMACEUTICALS, INC., 480 ARSENAL STREET, SUITE 110, WATERTOWN MA 02472

POINT Biopharma Global (POINT Biopharma Global) Headlines

From GuruFocus

POINT Biopharma to Participate in Upcoming Investor Conferences

By GuruFocusNews GuruFocusNews 07-08-2022

POINT Biopharma to Participate in Upcoming Investor Conferences

By Stock market mentor Stock market mentor 02-02-2023